Janssen/Legend’s Cilta-Cel Responses Could Make Up For Second-To-Market Position
Mitigation Strategy Lessens Neurotoxicity Of CAR-T In Myeloma
Cilta-cel likely will be the second BCMA-targeting CAR-T therapy approved in the US for multiple myeloma, but appears to have an efficacy advantage over BMS/bluebird’s first-to-market Abecma.
